These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11926966)

  • 1. An MCASE approach to the search of a cure for Parkinson's Disease.
    Klopman G; Sedykh A
    BMC Pharmacol; 2002 Apr; 2():8. PubMed ID: 11926966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy in Parkinson’s disease.
    Rose O
    Med Monatsschr Pharm; 2016 Jul; 39(7):286-92. PubMed ID: 29953181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease--levodopa complications.
    King DB
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S13-20. PubMed ID: 10451755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
    ; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
    Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the best initial treatment in Parkinson's disease?
    Sharp ME; Mazzoni P
    J R Coll Physicians Edinb; 2014; 44(4):291-2. PubMed ID: 25516899
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment Strategies in Early Parkinson's Disease.
    Marsili L; Marconi R; Colosimo C
    Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiating dopaminergic treatment in Parkinson's disease.
    Lang AE; Marras C
    Lancet; 2014 Sep; 384(9949):1164-6. PubMed ID: 24928806
    [No Abstract]   [Full Text] [Related]  

  • 13. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease.
    Hauser RA
    Evid Based Med; 2015 Feb; 20(1):17. PubMed ID: 25525039
    [No Abstract]   [Full Text] [Related]  

  • 15. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
    Petzer JP; Castagnoli N; Schwarzschild MA; Chen JF; Van der Schyf CJ
    Neurotherapeutics; 2009 Jan; 6(1):141-51. PubMed ID: 19110205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline for the treatment of Parkinson's disease.
    Carr J; Kies B; Fine J;
    S Afr Med J; 2009 Oct; 99(10):755-6, 758. PubMed ID: 20128276
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Rascol O
    Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.